欧洲幽门螺杆菌管理登记研究(Hp-EuReg):5年21 533例患者一线经验性根除处方模式与趋势及结局
该国际多中心前瞻性非干预登记研究纳入27个欧洲国家21 533例首次经验性幽门螺杆菌治疗患者,评估处方模式与根除结局。结果显示处方异质性大且与现行推荐不符,仅含铋四联或伴同疗法至少10天可达90%以上根除率,随时间推移根除有效性从84%升至90%。
要点
- 治疗前克拉霉素耐药率23%、甲硝唑耐药率32%、双重耐药率13%。
- 阿莫西林联合克拉霉素三联疗法最常用(39%),改良意向治疗根除率81.5%。
- 仅10天含铋四联或14天伴同疗法根除率超过90%。
核心结论
- 欧洲消化科医生对幽门螺杆菌感染的管理异质、欠佳且与现行推荐不一致。
- 仅持续至少10天的四联疗法能达到90%以上的根除率。
- 欧洲推荐正缓慢且异质地融入常规临床实践,并与有效性相应提高相关。
研究设计与样本
- 国际多中心前瞻性非干预登记研究,2013年开始,旨在评估欧洲消化科医生对幽门螺杆菌管理的决策与结局。
- 患者通过AEG-REDCap电子病例报告表登记,收集人口学、既往根除尝试、处方治疗、不良事件和结局等变量。
- 共评估来自27个欧洲国家的30 394例患者,其中21 533例(78%)首次经验性幽门螺杆菌治疗纳入分析。
主要发现
- 治疗前克拉霉素耐药率为23%,甲硝唑耐药率为32%,两者均耐药为13%。
- 阿莫西林联合克拉霉素三联疗法最常用(39%),改良意向治疗根除率为81.5%。
- 仅10天含铋四联疗法或14天伴同疗法获得超过90%的根除率。
- 更长治疗疗程、更高抑酸强度和依从性与更高根除率相关。
- 时间趋势分析显示处方呈地区依赖性转变,包括放弃三联疗法、使用更高抑酸和更长疗程,与总体有效性提高(84%-90%)相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. DESIGN: International multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed. RESULTS: 30 394 patients from 27 European countries were evaluated and 21 533 (78%) first-line empirical H. pylori treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14-day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%-90%). CONCLUSION: Management of H. pylori infection by European gastroenterologists is heterogeneous, suboptimal and discrepant with current recommendations. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates. European recommendations are being slowly and heterogeneously incorporated into routine clinical practice, which was associated with a corresponding increase in effectiveness.
引用
- Nyssen OP, Bordin D, Tepes B, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2020. PMID: 32958544. doi:10.1136/gutjnl-2020-321372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。